While the frequency of TP53 mutations is estimated to account for 10% of de novo AML cases, it rises strikingly in therapy-related AML or relapsing/refractory (R/R) AML cases, reaching up to 30% and 25%, respectively, in these groups (Daver et al., 2023a). The gene discussed is TP53; the disease is acute myeloid leukemia.